Kenvue Inc. Q1 2026 Financial Summary
Business Context and Reporting Period
This Form 10-Q covers the fiscal quarter ended March 29, 2026. Kenvue Inc. operates as a pure-play consumer health company with three reportable segments: Self Care, Skin Health and Beauty, and Essential Health. The company is currently in the process of a Pending Transaction to be acquired by Kimberly-Clark Corporation, approved by shareholders in January 2026, with closing expected in the second half of 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $3,909 million | $3,741 million |
| Gross Profit | $2,302 million | $2,168 million |
| Gross Margin | 58.9% | 58.0% |
| Operating Income | $767 million | $558 million |
| Net Income | $474 million | $322 million |
| Diluted EPS | $0.25 | $0.17 |
| Operating Cash Flow | $489 million | $428 million |
| Total Debt | $8,661 million | $8,524 million |
| Cash & Equivalents | $1,075 million | $1,057 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4.5% year-over-year. Organic sales grew 0.7%, driven by favorable value realization (1.0%) partially offset by volume declines (0.3%) due to lower illness incidence in pediatric Pain Care and Cough/Cold categories.
- Profitability: Operating income surged 37.5% to $767 million, and Net income rose 47.2% to $474 million. Gross margin expanded 90 basis points due to supply chain optimization, despite input cost inflation and tariff impacts.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased 5.5% to $1.453 billion, aided by restructuring savings and reduced separation-related costs.
- Restructuring: Restructuring expenses increased to $71 million (from $60 million) due to the initiation of the "2026 Restructuring Initiative," which targets $250 million in total charges for the fiscal year.
- Debt Repayment: The company redeemed $750 million of 5.35% Senior Notes due in 2026 during the quarter.
Guidance, Outlook, and Risks
- Pending Transaction: The merger with Kimberly-Clark remains subject to regulatory approvals. Shareholders will receive 0.14625 shares of K-C stock plus $3.50 cash per share. Transaction-related costs of $16 million were incurred in Q1 2026.
- Restructuring Outlook: The 2026 Restructuring Initiative aims to optimize the operating model and supply chain, with expected annualized pre-tax gross cost savings of approximately $200 million upon completion.
- Tariffs and Geopolitics: The company estimates an annualized gross tariff exposure of approximately $90 million. Ongoing conflict in the Middle East continues to create volatility in raw material and logistics costs.
- Legal Contingencies: Significant litigation risks persist regarding acetaminophen (autism/ADHD claims) and talc-based products (cancer claims). While J&J indemnifies Kenvue for U.S. and Canada talc liabilities, Kenvue remains liable for talc claims outside these regions. The company states it cannot reasonably estimate the magnitude of potential liability for these matters.
- Dividends: A quarterly dividend of $0.2075 per share was paid in February 2026, and another was declared in April 2026.
Investor Verification Checklist
- Merger Closing Conditions: Verify the status of foreign regulatory approvals required to consummate the Kimberly-Clark transaction.
- Restructuring Execution: Monitor the pace of the 2026 Restructuring Initiative and the realization of the projected $200 million in annualized savings.
- Litigation Exposure: Review updates on acetaminophen and talc litigation, specifically regarding the scope of indemnification from J&J and potential liabilities in non-U.S./Canada jurisdictions.
- Tariff Impact: Assess the actual financial impact of U.S. tariffs and potential refunds following the Supreme Court ruling on IEEPA tariffs.
- Organic Volume Trends: Track volume performance in the Self Care segment, which was negatively impacted by lower illness rates, to determine if this is a temporary or structural shift.